Cerenis Therapeutics raises €40 million in series C financing

Jean-Pierre Garnier appointed as non-executive director to the board

28-Jul-2010 - France

Cerenis Therapeutics SA announced it has raised €40 million in the first close of its series C financing. In this round €20 million came from the Fund for Strategic Investment (FSI) with an additional €20 million coming from the existing investors: Sofinnova Partners, HealthCap, Alta Partners and TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.

This third round of financing for Cerenis (Series C) will fund Phase II development of the lead Cerenis program, CER-001, an HDL-mimetic for the treatment of cardiovascular disease and to support the development of other new HDL therapies. This round of financing brings the total capital raised to date by the company to €107 million.

Appointment of Jean-Pierre Garnier

Cerenis also announced that Jean-Pierre Garnier, former CEO of GlaxoSmithKline and Pierre Fabre Laboratories, will join the Cerenis Board of Directors as a Non-Executive Director; and will be FSI’s representative on the board.

Other news from the department business & finance

These products might interest you

Whatman™ folded filter papers

Whatman™ folded filter papers by Cytiva

Whatman folded filter papers

Convenient folded formats speed up your sample preparation

filter papers
Systec H-Series

Systec H-Series by Systec

Safe, reproducible and validatable sterilization of liquids, solids and waste

Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications

laboratory autoclaves
Loading...

More news from our other portals

All FT-IR spectrometer manufacturers at a glance